Subscribe to RSS - BioScrip

BioScrip

In brief: VGM tallies costs by region, Option Care debuts in Louisiana

 - 
08/09/2018

WATERLOO, Iowa – The VGM Group has released the results of a “Delivery Cost Survey” that puts into perspective how costly it is for HME providers to provide patients with the necessary equipment.

Mobility lifts sales at Invacare; Inogen, BioScrip see revenue increases

 - 
08/08/2018

ELYRIA, Ohio – Invacare reported net sales of $246.2 million for the second quarter of 2018 compared to $233.5 million for the same period last year, about a 5.4% increase. It reported a net loss of $16.5 million vs. $23.5 million.

Executive appointments: Aeroflow, BioScrip

 - 
07/12/2018

Aeroflow Healthcare has named Scott Sonnone as CFO. He will play a vital role in expanding business for the Asheville, N.C.-based provider.

BioScrip revenues decline again

 - 
06/25/2018

DENVER – Inclement winter weather contributed to a decrease in net revenues during the first quarter of 2018 for BioScrip, which reported net revenues of $168.6 million down from $182.6 million in the fourth quarter of 2017.

BioScrip’s earnings decline

 - 
03/08/2018

DENVER – BioScrip reported net revenues of $182.6 million for the fourth quarter of 2017, down from $198.7 million in the third quarter.

Short takes: BioScrip, Rotech

 - 
01/10/2018

Denver-based BioScrip can now dispense and administer HEMLIBRA, a treatment for routine prophylaxis approved by the U.S. Food and Drug Administration.

BioScrip bolsters management team

 - 
11/28/2017

DENVER – BioScrip has added two new execs to its management team: Harriet Booker as senior vice president and COO, and Danny Claycomb as senior vice president of revenue cycle management.

‘Disruptors’ put a dent in BioScrip’s earnings

 - 
11/03/2017

DENVER – Company officials at BioScrip blamed a second straight quarter of net revenue declines on several “disrupters,” both expected and unexpected.

Short takes: BioScrip, Paragon Ventures, Stratice Healthcare, Invacare

 - 
10/05/2017

BioScrip is now dispensing and administering Radicava, the first treatment option for ALS approved by the U.S. Food and Drug Administration in more than 20 years…Paragon Ventures, a healthcare M&A firm, has launched paragonventures.com.

BioScrip revenues are down, but core product mix is up

 - 
08/11/2017

DENVER – BioScrip’s net revenues decreased 6.2% in the second quarter of 2017, but CEO Dan Greenleaf said in an earnings call the company was hitting targets.

Pages